Eli Lilly and UNICEF expand support for young people at risk of noncommunicable diseases
Betsy Goodfellow | May 30, 2024 | News story | Medical Communications | Eli Lilly, Pharmacy, Unicef, investment, noncommunicable diseases
Eli Lilly has announced that it will donate $6.5m to the United States Fund for UNICEF in order to expand UNICEF’s work to ‘improve the health outcomes of millions of children and youth at risk of noncommunicable diseases (NCDs) living in resource-limited settings in India’, according to the press release.
This investment was announced during the World Health Assembly held on 29 May 2024, and brings Eli Lilly’s total commitment since 2022 to over $20m.
UNICEF is expected to use the funding to address NCD risk factors, enhance health systems, strengthen the ability of healthcare practitioners to care for people and support millions of children and their families that are impacted by diseases including type 1 diabetes, respiratory illnesses, rheumatic and congenital heart disease, and sickle cell disease. The funding is intended to be used in resource-limited areas in India.
Luigi D’Aquino, chief of health at UNICEF India, commented: “UNICEF will work with governments and partners to strengthen health systems to effectively manage NCDs in children and young people. This will help integrate efforts into maternal, newborn and child health programmes, emphasising prevention and management of childhood NCDs.”
Cynthia Cardona, head of social impact at Eli Lilly, added: “UNICEF and Lilly share a similar goal – to make life better for millions of people around the world. These efforts are critical to working towards changing the global landscape of NCDs and improving health outcomes for children and adolescents living in resource-limited areas in India.”
Betsy Goodfellow
Related Content
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
Lilly’s drug for early Alzheimer’s shows promising results
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …
Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …
